Mr. Chair, I will respond in part and would recommend any follow-up with the National Research Council.
Indeed, the investment made has resulted in the construction of a biologics manufacturing centre. It is going through the final stages of its good manufacturing practice compliance and assessment of batches of vaccine produced there. It is being done through a partnership with Novavax to produce that vaccine.